Eli Lilly and Company announced topline results from the LIBRETTO-431 study evaluating Retevmo versus platinum-based chemotherapy plus pemetrexed – with or without pembrolizumab – as an initial treatment for patients with rearranged during transfection fusion-positive advanced or metastatic non-small cell lung cancer. The study met its primary endpoint, demonstrating a statistically significant and clinically meaningful improvement in progression-free survival. This result was based on a pre-specified interim efficacy analysis conducted by an independent data monitoring committee. Adverse events observed on Retevmo were generally consistent with those identified across the previously reported Retevmo development program.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LLY:
- NULG: Check Out This Large-Cap Growth ETF’s Strong Performance
- Eli Lilly price target raised to $510 from $475 at JPMorgan
- Next major rally in biotech likely not until end of 2024, says Capital One
- Eli Lilly announces SURMOUNT-3, SURMOUNT-4 trials met all primary endpoints
- VTI ETF’s Simple but Powerful Strategy is a Long-Term Winner